One case of euglycemic diabetic ketoacidosis caused by dapagliflozin used at a high altitude

doi:10.19803/j.1672-8629.20260364

Abstract

Abstract: Objective To investigate the adverse drug reaction of euglycemic diabetic ketoacidosis (euDKA) associated with dapagliflozin used in high-altitude areas in order to provide a reference for safe and rational drug use. Methods A case of euDKA in a 26 year old type 2 diabetes patient with long term high altitude residence and after prolonged use of dapagliflozin was analyzed. The risk factors and strategies for prevention and treatment were studied based on literature review. Results Dapagliflozin was discontinued immediately after admission, and the patient received fluid resuscitation and low dose intravenous insulin. The acidosis was corrected and ketones turned negative. Based on correlation analysis, the causal relationship between dapagliflozin and euDKA was determined as “probable”. Conclusion The use of dapagliflozin in high-altitude hypoxic environments may elevate the risk of euDKA, warranting increased clinical vigilance, prompt identification, and immediate interventions to ensure safe medication.

Key words: Dapagliflozin, SGLT2 Inhibitor, Euglycemic Diabetic Ketoacidosis, High Altitude Hypoxia, Adverse Drug Reaction

CLC Number:

Wang Huanping, Fang Wei, Zhu Hongxia. One case of euglycemic diabetic ketoacidosis caused by dapagliflozin used at a high altitude[J]. Chinese Journal of Pharmacovigilance, 2026, 23(10): 1175-1177.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/10.19803/j.1672-8629.20260364

https://zgywjj.magtechjournal.com/EN/Y2026/V23/I10/1175

References

[1] Chinese Diabetes Society.Guidelines for the prevention and treatment of type 2 diabetes mellitus in China (2024 edition)[J]. Chinese Journal of Diabetes Mellitus(中国糖尿病杂志), 2025, 17(1): 16-139.
[2] American Diabetes Association Professional Practice Committee. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2024[J]. Diabetes Care, 2024, 47(Suppl 1): S158-S178.
[3] Yoshida Y, Fujimoto Y, Konishi H, et al.Euglycemic diabetic ketoacidosis in a patient with type 2 diabetes and preserved insulin secretion on empagliflozin[J]. Internal Medicine, 2025, 64(14): 2183-2188.
[4] He Z, Lam K, Zhao W, et al.SGLT-2 inhibitors and euglycemic diabetic ketoacidosis/diabetic ketoacidosis in FAERS: a pharmacovigi-lance assessment[J]. Acta Diabetologica, 2023, 60(3): 401-411.
[5] Goldenberg R M, Berard L D, Cheng A Y Y, et al. SGLT2 inhibitor-associated diabetic ketoacidosis: Clinical review and recommendations for prevention and diagnosis[J]. Clinical Therapeutics, 2016, 38(12): 2654-2664. e1.
[6] Morace C, Lorello G, Bellone F, et al.Ketoacidosis and SGLT2 inhibitors: a narrative review[J]. Metabolites, 2024, 14(5): 264.
[7] Xi L, Chow C M, Kong X.Role of tissue and systemic hypoxia in obesity and type 2 diabetes[J]. Journal of Diabetes Research, 2016, 2016: 1527852.
[8] Albogami S, Hassan A, Abdel-Aziem S H, et al. Effects of combination of obesity, diabetes, and hypoxia on inflammatory regulating genes and cytokines in rat pancreatic tissues and serum[J]. PeerJ, 2022, 10: e13990.
[9] Long B, Lentz S, Koyfman A, et al.Euglycemic diabetic ketoacidosis: etiologies, evaluation, and management[J]. American Journal of Emergency Medicine, 2021, 44: 157-160.
[10] Blau J E, Tella S H, Taylor S I, et al.Ketoacidosis associated with SGLT2 inhibitor treatment: analysis of FAERS data[J]. Diabetes/Metabolism Research and Reviews, 2017, 33(8): e2924.
[11] Douros A, Lix L M, Fralick M, et al.Sodium-glucose cotransporter-2 inhibitors and the risk for diabetic ketoacidosis: a multicenter cohort study[J]. Annals of Internal Medicine, 2020, 173(6): 417-425.
[12] Juneja D, Nasa P, Jain R, et al.Sodium-glucose cotransporter-2 inhibitors induced euglycemic diabetic ketoacidosis: a meta summary of case reports[J]. World Journal of Diabetes, 2023, 14(8): 1314-1322.
[13] Dutta S, Kumar T, Singh S, et al.Euglycemic diabetic ketoacidosis associated with SGLT2 inhibitors: a systematic review and quantitative analysis[J]. Journal of Family Medicine and Primary Care, 2022, 11(3): 927-940.
[14] Cai Jun, Liu Si min, Li Huixin, et al. Literature analysis of dapag-liflozin-induced euglycemic diabetic ketoacidosis[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2020, 17(11): 808-812.
[15] Gandecka-Pempera A, Naskręt D, Adamska A, et al.Severe euglycemic ketoacidosis following combined therapy with GLP-1 receptor agonist and SGLT-2 inhibitor, refractory to standard treatment: a case report[J]. Frontiers in Endocrinology (Lausanne), 2025, 16: 1649270.
[16] Briones-Claudett K H, Benites-Solis J, Delgado-Cedeño P, et al. Case report: high-altitude exposure and severe respiratory infection precipitating diabetic ketoacidosis: new-onset ketosis-prone diabetes unmasked by physiological stress[J]. Frontiers in Medicine (Lausanne), 2026, 13: 1762878.
[17] Center for drug evaluation, national medical products administration. Guidance for clinical evaluation of adverse event relevance in clinical trials (for trial implementation)[S]. Beijing: Center for Drug Evaluation, 2024.
[18] Shukla R, Shrestha P, Khanal B, et al.Euglycemic diabetic ketoacidosis: clinical suspicion and diagnosis[J]. Clinical Medicine Insights: Endocrinology and Diabetes, 2026, 19: 11795514261431390.
[19] Umpierrez G E, Davis G M, Elsayed N A, et al.Hyperglycemic crises in adults with diabetes: a consensus report[J]. Diabetes Care, 2024, 47(8): 1257-1275.
[20] Handelsman Y, Henry R R, Bloomgarden Z T, et al.American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the association of SGLT-2 inhibitors and diabetic ketoacidosis[J]. Endocrine Practice, 2016, 22(6): 753-762.
[21] Adeva-Andany M M, Adeva-Contreras L, Carneiro-Freire N, et al. The impact of high altitude (hypobaric hypoxia) on insulin resistance in humans[J]. Journal of Physiology and Biochemistry, 2025, 81(1): 35-55.